Genome ReviewIs It the Right Payment Solution for Your iGaming Business?

Genome is a Bank of Lithuania-licensed Electronic Money Institution operating under UAB "Maneuver LT" (company code 304785124). The EMI license has been in force since 2018 and the company ranked 5th-largest Lithuanian EMI by client-fund turnover in Q3 2024. PCI DSS, PSD2, GDPR and DORA compliance are in place. The regulatory shell is real and the financials (2024 revenue €9.35M, profit €1.85M, total assets €135M) are public. The reputation risk is the Trustpilot 1-star tail — 41% of reviews — which reflects compliance friction more than payment failure. For a regulated EU operator with clean documentation, Genome is a credible payments partner. For operators with shaky compliance documentation, the AML-review friction will surface.

Genome doesn't publish merchant card-acquiring rates. The pricing structure splits into a low-risk track and a high-risk track, with the iGaming-card rate landing in the 2.5-4.5% range per operator reports — in line with EU high-risk PSP norms. SEPA Instant is priced at the same rate as SEPA Credit, which is the real differentiator. Funds-safekeeping fee is 0.01% (minimum €3) on stuck balances. Rolling reserve is set per merchant after KYB, not a published schedule. No published minimum monthly volume, no published contract length. Get the SEPA-rail commitment in writing and benchmark card pricing against Solidgate's published 0.3-0.8% + acquiring.

Yes, and pricing it at the same rate as standard SEPA Credit is the headline differentiator. Most EU EMIs add a per-transaction premium for Instant. Genome doesn't. Batch payouts support up to 3,000 transfers per API call across SEPA Instant + SEPA Credit. For an operator pushing daily player withdrawals or monthly affiliate commissions inside the Eurozone, that's a structurally cheaper payout rail than most PSP alternatives. SEPA Instant clears in 10 seconds or less, day or night, all year.

No. Genome's merchant terms explicitly prohibit accepting or sending payments in crypto or unregulated virtual currency. The account can transact with regulated crypto exchanges as a counterparty — sending fiat to Binance or Kraken and receiving fiat back — but there is no on/off-ramp inside the platform, no USDT/USDC settlement, no Bitcoin acceptance. Crypto-first casinos need a separate provider like CoinsPaid, NOWPayments or BitPay alongside Genome.

EEA (27 EU member states) plus the UK and a small list of EEA-adjacent jurisdictions. Merchant onboarding is limited to EU/EEA-licensed entities — offshore-only operators are typically declined. No US merchant acquiring, no LATAM coverage, no APAC. Approximately 38 countries in total. This is the most material limitation versus globally-licensed PSPs like Nuvei (50+ markets) or Checkout.com (150+). Genome is a European regional specialist, not a global PSP.

Technical integration runs 1-2 weeks against the developers.genome.eu REST API. Pay-ins, payouts and webhook endpoints documented separately. HmacSHA256 webhook signing, exponential-backoff retry, sandbox with test card numbers. The catch is what's missing: no public GitHub organization, no open-source SDKs, no CMS plugins, and zero pre-built iGaming platform connectors. Nuvei has six platform connectors (SoftSwiss, EveryMatrix, Bragg, Altenar, BetConstruct, Slotegrator), Paysafe has four. With Genome you build custom against raw REST. KYB onboarding adds another 1-3 weeks depending on risk profile.

Different product categories that overlap on iGaming positioning. MiFinity is an iGaming-focused closed-loop eWallet with 80+ funding methods, FCA + MFSA dual licensing and 1,300+ live iGaming sites integrated through Slotegrator's Moneygrator and SoftSwiss's FinteqHub. Genome is a Bank of Lithuania EMI with card acquiring, SEPA Instant, Open Banking and dedicated business IBANs. MiFinity sits inside an operator's cashier as an alternative payment method. Genome operates as the operator's underlying merchant account and payout rail. They're complements, not alternatives — many operators run both.

Polarized review distributions are common for EMIs serving high-risk verticals. The 1-star reviews cluster on three themes: incoming transfers frozen during AML review with terms cited that users say weren't clearly explained, account closures after extended verification cycles with documentation requests that feel endless, and money held during compliance review with slow customer-service response. The pattern is consistent with the structural friction of running strict AML compliance from a Lithuanian EMI shell — the regulator is stricter than the marketing suggests, and customers experience that friction as Genome's fault. Wise and Revolut have had similar polarized periods. It's a sector pattern more than a Genome-specific failure.

Not via pre-built connectors. There is no off-the-shelf SoftSwiss FinteqHub connector, no EveryMatrix integration, no Slotegrator Moneygrator slot. Integration with any of these platforms is custom development against Genome's REST API on the operator side. For operators that need plug-and-play platform connectors, Nuvei (six platforms), Paysafe (four), AstroPay (two) and PayRetailers (two) are all stronger choices. Genome's pitch is the payment rail itself, not the platform plumbing.

Genome's Bank of Lithuania EMI license covers payment-services compliance — PSD2, AML, GDPR, DORA, PCI DSS. It does not replace a gambling regulator license on the operator side. You still need MGA, UKGC, Curacao, Anjouan or whatever jurisdiction your iGaming operation is licensed under. The EMI shell handles the payments compliance layer; the gambling shell handles the gaming compliance layer. They sit on top of each other rather than overlapping. Operators sometimes assume the EMI license substitutes for the gambling license — it doesn't.